secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001213900-26-049347
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology ships first international LYMPHIR order to Europe via NPPs
--------------------------------------------------------------------------

- Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.
- Access via Named Patient Programs (NPPs) in local countries; no EMA marketing authorization.
- LYMPHIR FDA-approved Aug 2024 for relapsed/refractory CTCL; US commercial launch in Dec 2025.
- Company continues US launch with progress on formulary access, payer coverage, and physician engagement.
- CEO Leonard Mazur cites commitment to expanding patient access beyond the US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/0001213900-26-049347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/ea0288202-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-049347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer